ERADICATE: A phase Ib/II study of elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer
Trial Description
The goal of this study is to evaluate the safety and efficacy of elacestrant in
combination with trastuzumab deruxtecan (T-DXd) in participants with hormone
receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is
resistant to prior CDK4/6 inhibitor and endocrine therapy.
The names of the study drugs involved in this study are:
- Elacestrant (a type of selective estrogen receptor degrader)
- Trastuzumab deruxtecan (a type of standard of care antibody drug conjugate)
Eligibility Requirements
Inclusion Criteria:
- Participants must have a histologically or cytologically confirmed diagnosis of
HR+/HER2-low metastatic or unresectable locally advanced breast cancer, defined as
ER ≥ 10%, any PR in the most recent sample and HER2-low (IHC 1+ or IHC 2+ and ISH
non-amplified) or HER2-ultralow (IHC 0 and any membranous staining on any prior
primary or metastatic sample). Cutoff values for positive/negative HER2 staining
should be in accordance with current ASCO/CAP (American Society of Clinical
Oncology/College of American Pathologists) guidelines.76
- Participants must have had prior CDK4/6 inhibitor and may have any number of prior
endocrine based therapies in the metastatic setting.
- Participants may have progressed on up to 1 prior line of prior chemotherapy or ADC
in the metastatic setting.
- Participants must have measurable disease per RECIST 1.1 criteria. See Section 11
for the definition of measurable disease. Participants must have measurable disease,
defined as at least one lesion that can be accurately measured in at least one
dimension (longest diameter to be recorded for non-nodal lesions and short axis for
nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan,
MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the
evaluation of measurable disease.
- Participants must have known ESR1 mutation status in tumor or ctDNA within 6 months
of enrollment to the trial. Participants must have Guardant360 CDx testing for
ESR1-mutation status if status has not been validated within 60 days of
registration.
- Women or men age ≥18 years are eligible.
- ECOG performance status ≤ 2.
- Participants must have adequate organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9.0 g/dL
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 2 x ULN
in patients with documented Gilbert's syndrome)
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional ULN (or < 5 x ULN in patients with
liver metastases)
- Creatinine ≤ 1.5 x institutional ULN OR
- Calculated creatinine clearance ≥ 45 mL/min via the Cockcroft-Gault formula for
participants with creatinine levels above institutional ULN
- Baseline LVEF ≥ 50% prior to registration, as measured by echocardiogram (or
multiple-gated acquisition [MUGA] scan if an echocardiogram cannot be performed
or is inconclusive).
- Participants with a history of central nervous system (CNS) metastases are
eligible if: Stable or untreated, asymptomatic brain metastases not needing
immediate local therapy. For patients with untreated CNS lesions > 2.0 cm on
screening contrast brain MRI, discussion with and approval from the Sponsor
Investigator is required prior to enrollment.
1. Brain metastases previously treated with local therapy may either be
stable since treatment or may have progressed since prior local CNS
therapy, provided that there is no clinical indication for immediate
re-treatment with local therapy in the opinion of the investigator
2. Patients treated with CNS local therapy for newly identified lesions may
be eligible to enroll if all of the following criteria are met: Time since
WBRT is ≥ 14 days prior to first dose of treatment, time since SRS is ≥ 7
days prior to first dose of treatment, and time since surgical resection
is ≥ 14 days
- Postmenopausal women must be postmenopausal, which is defined as any of the
following:
- Age ≥ 60 years
- Age < 60 and amenorrhea for 12 or more months (in the absence of chemotherapy,
tamoxifen, toremifene, or ovarian suppression) and FSH, and estradiol in the
postmenopausal range per local normal range
- Premenopausal women made postmenopausal through the use GnRH agonist prior to
study entry are eligible and MUST remain on the GnRH agonist for the duration
of protocol treatment.
- Status-post bilateral oophorectomy - After adequate healing post-surgery
- Premenopausal women must have a negative serum or urine pregnancy test. Pregnancy
testing does not need to be pursued in female participants who are postmenopausal
according to the definition in 3.1.10.
- Women of child-bearing potential and men must agree to use adequate contraception at
time of enrollment and for 4 months after the last dose of elacestrant or 7 months
after the last dose of trastuzumab deruxtecan, whichever is later.
- Participants must be able to swallow and retain oral medication.
- Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
- Prior treatment with aatopoisomerase inhibitor antibody drug conjugate in any
setting.
- Prior treatment with an oral novel estrogen receptor degrader or modulator in the
metastatic setting (SERD, SERM, PROTAC, or CERAN). Prior fulvestrant is allowed. A
washout period of 7 days is required for any endocrine or targeted therapy. A
washout period of 14 days is required for any chemotherapy.
- Patients with known brain metastases that are symptomatic or that require therapy
for symptom control are not eligible. Patients with stable or asymptomatic brain
metastases are allowed. Participants with CNS metastases treated by neurosurgical
resection or brain biopsy performed within 4 weeks before day 1 of study therapy
will be excluded.
- Receipt of any other investigational compound or device within 2 weeks of the first
dose of treatment in this study.
- History of allergic reactions attributed to compounds of similar chemical or
biologic composition to elacestrant or T-DXd.
- History of (non-infectious) pneumonitis that required steroids or current ILD by
imaging at screening.
- Patients who are pregnant or breastfeeding, or who expect to become pregnant within
the projected duration of the study.
- Patients with active tuberculosis.
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active
infection requiring systemic therapy, clinically significant cardiovascular disease
including: cerebral vascular accident/stroke (< 6 months prior to enrollment),
myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive
heart failure (≥ New York Heart Association Classification Class II), or serious
cardiac arrhythmia requiring medication, uncontrolled diabetes mellitus,
gastrointestinal disorders potentially affecting the absorption of elacestrant,
inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or total
gastric resection, or psychiatric illness/social situations that would limit
compliance with study requirements. Moderate or severe hepatic impairment
(Child-Pugh B or C). Active hepatitis B or active hepatitis C infection. Ability to
comply with study requirements is to be assessed by each investigator at the time of
screening for study participation. History of myocardial infarction, acute coronary
syndrome or coronary angioplasty/stenting/bypass grafting within the last six months
OR congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or
history of CHF NYHA Class III or IV.
- Patients with a history of different malignancy are ineligible, except for those who
have been disease-free for at least three years and are deemed by the investigator
to be at low risk for recurrence of the prior malignancy. Individuals with the
following cancers are eligible if diagnosed and treated within the past 5 years:
ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell or
squamous cell carcinoma of the skin.